Truist raised the firm’s price target on ANI Pharmaceuticals (ANIP) to $77 from $65 but keeps a Hold rating on the shares after its Q2 earnings beat. The management boosted the product’s guide which also coincided with commentary heard from the competition, even though the company’s Iluvien market access challenges remain and generics performed inline, the analyst tells investors in a research note. Truist adds that the ANI valuation at 10-times EBITDA warrants a neutral stance.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIP:
- ANI Pharmaceuticals Reports Record Growth in Q2 2025
- ANI Pharmaceuticals price target raised to $93 from $84 at H.C. Wainwright
- ANI Pharmaceuticals price target raised to $94 from $80 at Piper Sandler
- Morning Movers: Under Armour sinks following second quarter earnings
- ANI Pharmaceuticals reports Q2 adjusted EPS $1.80, consensus $1.42